Quantification of circulating varicella-zoster virus DNA for follow-up in a case of visceral varicella-zoster infection ameliorated with intravenous acyclovir.
We describe a patient with acute lymphocytic leukemia (ALL) who developed visceral varicella-zoster virus (VZV) infection following cord blood stem cell transplantation (CBSCT) and was successfully treated with intravenous acyclovir (ACV). A 24-year-old woman with ALL developed severe epigastric pain 168 days after CBSCT, followed by blistering eruptions 2 days later. A diagnosis of visceral varicella-zoster disease was made, and early intravenous ACV therapy successfully alleviated the epigastric pain and skin lesions within 2 weeks. Polymerase chain reaction analysis of the serum showed dramatic decreases in the viral DNA copy number and revealed large viral concentrations prior to the skin manifestations. The viral DNA copy number in whole blood remained positive, however, but was reduced. Further treatment with intravenous ACV led to VZV DNA becoming undetectable in whole blood, a result not achieved with oral valacyclovir.
Ishizawa
Jo
J
Department of Hematology, Shizuoka Red Cross Hospital, Shizuoka, Japan.
Fujita
Hiroyuki
H
Iguchi
Mai
M
Tachibana
Takayoshi
T
Taguchi
Jun
J
Ishigatsubo
Yoshiaki
Y
D000212:Acyclovir / Q000008:administration & dosage*; D000328:Adult; D000998:Antiviral Agents / Q000008:administration & dosage*; D036101:Cord Blood Stem Cell Transplantation / Q000009:adverse effects; D004279:DNA, Viral / Q000097:blood / Q000187:drug effects; D005260:Female; D006562:Herpes Zoster / Q000150:complications* / Q000188:drug therapy*; D014645:Herpesvirus 3, Human / Q000187:drug effects* / Q000276:immunology; D006801:Humans; D007275:Injections, Intravenous; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000628:therapy; D014781:Viscera / Q000821:virology*
D000998:Antiviral Agents; D004279:DNA, Viral; D000212:Acyclovir